Replies to post #385554 on Innovation Pharmaceuticals Inc (IPIX)

[sunspotter]

“Had one (1) less patient died on treatment arm then things would look very different now.”

No, they wouldn’t. A difference of one or two deaths either way wouldn’t have been statistically or clinically significant.

And in any event it wouldn't have affected the primary endpoint (mortality was a secondary endpoint).

I may have mentioned before that the study was underpowered.

And that it pays to understand the basics of clinical research before gamblin real money on an OTC penny stock would-be biotech.